Lead Product(s) : N-Acetyl-D-Leucine
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Sanford Burnham Prebys
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DS-1211 is a potent and specific small-molecule inhibitor of TNAP. In vitro studies characterized the mode of inhibition and inhibitory effects of DS-1211 on three human ALP isozymes-TNAP, human intestinal ALP, human placental ALP.
Brand Name : DS-1211
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 01, 2022
Lead Product(s) : N-Acetyl-D-Leucine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Sanford Burnham Prebys
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?